Aldeyra Therapeutics, Inc. (ALDX)
1.48
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
1.48
0.00 (0.00%)
After-Hours: 20:00
Aldeyra Therapeutics Research and Development Expense (Quarterly) : 3.484M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.484M |
| March 31, 2026 | 2.410M |
| December 31, 2025 | 4.304M |
| September 30, 2025 | 5.431M |
| June 30, 2025 | 8.505M |
| March 31, 2025 | 7.423M |
| December 31, 2024 | 14.63M |
| September 30, 2024 | 12.44M |
| June 30, 2024 | 14.97M |
| March 31, 2024 | 6.184M |
| December 31, 2023 | 4.298M |
| September 30, 2023 | 6.962M |
| June 30, 2023 | 6.963M |
| March 31, 2023 | 11.24M |
| December 31, 2022 | 8.962M |
| September 30, 2022 | 11.54M |
| June 30, 2022 | 14.57M |
| March 31, 2022 | 12.23M |
| December 31, 2021 | 12.84M |
| September 30, 2021 | 12.89M |
| June 30, 2021 | 11.47M |
| March 31, 2021 | 7.726M |
| December 31, 2020 | 7.028M |
| September 30, 2020 | 6.134M |
| June 30, 2020 | 4.886M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.634M |
| December 31, 2019 | 9.614M |
| September 30, 2019 | 16.22M |
| June 30, 2019 | 10.66M |
| March 31, 2019 | 7.849M |
| December 31, 2018 | 8.549M |
| September 30, 2018 | 7.881M |
| June 30, 2018 | 6.793M |
| March 31, 2018 | 6.600M |
| December 31, 2017 | 5.545M |
| September 30, 2017 | 3.539M |
| June 30, 2017 | 3.849M |
| March 31, 2017 | 3.369M |
| December 31, 2016 | 3.447M |
| September 30, 2016 | 3.380M |
| June 30, 2016 | 2.834M |
| March 31, 2016 | 3.512M |
| December 31, 2015 | 3.112M |
| September 30, 2015 | 2.076M |
| June 30, 2015 | 1.249M |
| March 31, 2015 | 1.136M |
| December 31, 2014 | 1.404M |
| September 30, 2014 | 1.196M |
| June 30, 2014 | 0.6639M |
| March 31, 2014 | 0.4443M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |
| Sarepta Therapeutics, Inc. | 91.26M |
| Anixa Biosciences, Inc. | 1.258M |